INTRODUCTION
Ovarian cancer is the most lethal gynecologic malignancy in Western populations, resulting in the death of approximately 125,000 women globally per year 1, 2 . Despite approximately 30 years of clinical trials with many different chemotherapeutic regimes and targeted therapies; cytoreductive surgery along with platinum and taxane chemotherapy remain the international standard of care for this cancer 3 . Relapse rates are high and there is an urgent need to identify prognostic and predictive biomarkers for this cancer. High grade serous carcinoma (HGSC) accounts for approximately 70% of ovarian cancer cases and the vast majority of deaths 4 . There is now compelling evidence that most cases arise from the fimbria of the fallopian tube and are more accurately categorised as tubo-ovarian HGSCs [5] [6] [7] . Germline and somatic BRCA1 and BRCA2 mutations in HGSC is associated with enhanced survival that is largely attributed to a better response to platinum chemotherapy [8] [9] [10] [11] . Reduced BRCA1 mRNA and protein expression was also previously
shown to be prognostic in epithelial ovarian carcinoma (EOC) [12] [13] [14] and predictive of response to both platinum and taxane chemotherapy 14 . Indeed, the evaluation of the BRCA phenotype or "BRCAness" lead to the identification of deficiencies in several homologous repair pathway genes that are also associated with enhanced survival and platinum responses 15, 16 . Similarly, the study of other BRCA-related genes may further stratify chemotherapy responses in tubo-ovarian HGSC.
The mitotic arrest deficiency protein 2 (MAD2) is a transcriptional target of BRCA1
17
. MAD2 is an essential spindle assembly checkpoint protein monitoring accurate chromosomal alignment at the metaphase plate before mitosis 18, 19 . A predominance of evidence implicates the overexpression of MAD2 as a driver of chromosomal instability (CIN) in many cancer types 20 . Although MAD2 overexpression is largely associated with tumours in which the retinoblastoma protein (Rb) or p53 tumour suppressor proteins are also inactivated, MAD2 overexpression per se is sufficient to cause 
MATERIALS AND METHODS

Tumour Samples and Patient Characteristics
A tissue microarray (TMA) (Beecher Instruments, Silver Springs, MD, USA) was constructed using 0.6 mm tissue cores of EOC cases that were retrospectively identified through the Northern Ireland were excluded from the study. Of the 94 patients, all except three received adjuvant carboplatin or cisplatin and 74 patients also received a taxane. Six patients received a combination of a platin with a taxane and either erlotinib (2 patients) or gemcitabine (4 patients). The treatment of three patients is unknown. Cytoreductive status was defined as no visible residual disease, less than 1cm, more than 1 cm. All the cases were from patients who had cytoreduction. Table 1 shows clinicopathological features of the 94 cases included in this study.
Immunohistochemistry
The TMAs were stained with MAD2 primary antibody (BD Biosciences, CAT#610678) at a 1:100 dilution using the Ventana Discovery XT immunostainer and standard immunohistochemical techniques as previously published (Furlong et al., 2012). BRCA1 staining was performed using the mouse anti-BRCA1 (AB-1) mouse monoclonal (MS110) antibody (Calbiochem, UK) at a 1:200 dilution as previously described 14, 41 .
Evaluation of BRCA1 and MAD2 Immunostaining
Three BRCA1 and MAD2 stained slides (which were derived from two immediately adjacent tissue sections of the TMA) were scored independently by 3 observers (TB, LN and WGM). Only cores containing >20% tumour were scored. Each core was assessed for maximum nuclear staining intensity and assigned a score of negative (0), weak (1), intermediate (2) and strong (3) 31,32
. A mean nuclear staining intensity was then calculated by averaging positive staining across all 4 cores and rounded up to give whole numbers; low mean nuclear intensity was regarded as scores of 0, 1 and high mean nuclear intensity as scores of 2,3. The percentage distribution of maximum nuclear staining was also recorded in the following categories; no staining was assigned a score of 0, <10%
was assigned a score of 1, 10 -25% was assigned a score of 2, 26 -50% was assigned a score of 3, 51
-75% was assigned a score of 4, >75% was assigned a score of 5 41 . A quickscore was calculated by multiplying maximum nuclear intensity with corresponding distribution category
32
. This gave a maximum score of 15. Distribution groupings were assessed by median distribution or by categorising distribution as low (≤7.5) or high (>7.5). (2); and resistant is defined as disease free for < 6 months (3).
Statistical analyses
RESULTS
Statistical analysis of the association between BRCA1 and MAD2 expression in EOC.
To ensure that each tumour was well represented in the TMA, only cases in which BRCA1 and MAD2
were assessable across all 4 tissue cores were included in the assessment. The ICC for agreement between scores ranged above 0.7; this confirmed excellent agreement in the scoring. In our analysis, mean nuclear intensity was consistently more informative than the quickscore and therefore, all data presented in this study were correlated with mean nuclear intensity.
Representative staining is demonstrated in Figure 1 . Maximum BRCA1 and MAD2 nuclear staining intensity was assessed in 4 tissue cores representing 94 cases. This resulted in 376 observations and the frequencies of the maximum BRCA1 and MAD2 nuclear expression are recorded in supplemental Statistical analysis of BRCA1 and MAD2 mean nuclear staining intensity.
Both BRCA1 and MAD2 immunohistochemical expression have been assessed previously in EOC and have been shown to be associated with survival in patients with EOC in general and in the subset of HGSC. In this study, we adopted a mean nuclear staining intensity which was superior to a quickscore in demonstrating that tumours which had a mean intensity score of zero for BRCA1
(BRCA1 negative) were significantly associated with an improved DSS in HGSC (HR, 3.305; (95% CI, 1.849 -5.909), log rank, p < 0.0001) (Figure 2 , supplemental Table 2 ). This is consistent with previous studies of BRCA1 immunohistochemistry in EOC and with the consensus that loss of BRCA1
is associated with improved chemotherapy response. A chi-squared analysis revealed that negative BRCA1 expression was significantly associated with sensitivity to chemotherapy in this patient cohort (Supplemental Table 3 Table 2 ) . A chi-squared analysis also revealed that low MAD2 expression was significantly associated with sensitivity to chemotherapy in this patient cohort (Supplemental Table 3 , p = .0038) and is consistent with the observation that BRCA1
expression is significantly associated with MAD2 expression.
Statistical analysis of BRCA1 and MAD2 co-expression
As there is a significant association between BRCA1 and MAD2 expression, the co-expression of these two proteins could be a more informative assessment of BRCA1 function in tumour cells and we aimed to determine if this could more accurately predict patient survival. Our results showed a significant association with DSS with BRCA1 and MAD2 co-expression (HR, 2.908; (95% CI, 1.592 -5.312), log rank, p =0.0001) (Figure 4 , supplemental . Secondly, we also demonstrate that MAD2 is prognostic in HGSC.
However, contrary to previous studies, low MAD2 expression associated with improved DSS in this patient cohort. In a recent meta-analysis of MAD2 expression in all cancers, low MAD2 levels were more consistently associated with better survival, in keeping with the results of our study 26 . One limitation to our study is that the numbers are relatively small with few cases of negative BRCA1 and high MAD2 expression or positive BRCA1 and low MAD2 levels. Therefore, survival associated with MAD2 in this study was predominantly driven by BRCA1 expression.
The levels of MAD2 can influence many features of tumour initiation and progression and so it is not surprising that MAD2 expression is associated with prognosis in various cancers. Contrary to all other cancers tested, low levels of MAD2 were surprisingly and uniquely shown to be a poor prognostic indicator in EOC. We now report in this study that low levels of MAD2 is associated with improved DSS in HGSC. As BRCA1 deficiency is currently the best indicator of survival in HGSC (outside of traditional factors such as tumour stage, age and cytoreductive status), it would appear more logical that deficiencies in a BRCA1 transcriptional target would also predict better outcome. Of note, one major difference between this study and all prior studies is that the pathological review of the EOC samples in this patient cohort was recent using modern diagnostic criteria; previously there was significant interobserver variability amongst pathologists in the classification of EOC. . As we have already discussed, we were unable to assess the survival of cases that stained positive for BRCA1 with low MAD2 expression and those which were negative for BRCA1
and with high MAD2 expression, since so few cases stratified into these groupings. We would expect that low BRCA1 would have a greater influence on survival in such cases and it is conceivable that in this instance, high MAD2 would be associated with improved survival. We also employed stringent inclusion criteria for our study and only included cases with interpretable scoring in all 4 TMA cores; previous studies may have been influenced by poor tumour representation on the TMA.
This study highlights problematic aspects of using MAD2 immunohistochemistry as a biomarker in which either up-or down-regulation of the gene can result in similar genomic aberrations and contribute to poor patient survival 43, 44 . Through in vitro and in vivo investigation, high MAD2 levels are known to correlate with increased cellular proliferation, cellular transformation, migration, invasiveness and cancer metastasis [45] [46] [47] , while other studies have shown that low MAD2 expression has a role in chemoresistance to both DNA-damaging agents 48,49 and anti-microtubles 27, 31 .
Considering the heterogeneous nature of HGSC, a better understanding of the molecular subtypes could help inform the adverse role of up-or down-regulation of MAD2 on patient survival and whether it is dependent on BRCA1 levels or activity. In the absence of any major breakthrough in early detection of HGSC, patient stratification methods to predict response to therapy are extremely valuable and the role of MAD2 in chemoresistance could be informative. Future studies could focus on relating MAD2 expression to chemoresponse in which the analysis of the MAD2 conformation specific antibodies would provide an assessment of the tissue expression of the active form of MAD2. Supplemental Table 2 . Cox regression analysis and hazard ratios (HRs) with 95% confidence intervals (CIs) for disease specific survival (DSS) adjusting for age at diagnosis, disease stage and optimal surgical debulking. 
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